Abu Dhabi's M42 to roll out genomics program in Botswana
The 10-year contract with the government of Botswana includes a national genomics program and will digitize health records and bolster access to medicines.
Abu Dhabi-based healthcare firm M42 has inked a 10-year agreement with the government of Botswana to implement a nationwide genomics program, digitize health records, and enhance access to medications. The collaboration between G42 and Mubadala-backed M42, as reported by Semafor, stems from the company's ambition to expand operations in developing nations, which it perceives as a prime opportunity for nations to "leapfrog legacy systems," according to Moulavasilis, the CEO.
This partnership with Botswana's Ministry of Health encompasses a population-wide genomic sequencing initiative, which promises to amass vital data to facilitate the early detection of treatable ailments. Furthermore, the accord aims to enhance pharmaceutical and medical supply chains through Mubadala Bio's life sciences division.
While the project's timeline remains undisclosed, this agreement represents one of the UAE's most substantial healthcare investments and marks M42's inaugural government-level deal in Africa. This region grapples with a disproportionate disease burden relative to its healthcare infrastructure.
Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
